TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8696533

Group type: EXPERIMENTAL
Intervention: Bezafibrate (group B, n = 21)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No lipid-lowering treatment (group C, n = 22)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No treatment (group A, n = 52)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Bezafibrate (group B)
Number of subjects: 95

Group type: COMPARATOR
Intervention: No lipid-lowering treatment (group C)
Number of subjects: 95
Study: 1978497

Group type: EXPERIMENTAL
Intervention: Remoxipride 100-300 mg/day (n = 60)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Remoxipride 200-600 mg/day (n = 61)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Haloperidol 10-30 mg/day (n = 64)
Number of subjects: 186
Study: 351394

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Aspirin (Men)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Combination of Aspirin and Sulfinpyrazone
Number of subjects: 585
Study: 31694579

Group type: EXPERIMENTAL
Intervention: Colonoscopy with polypectomy/endoscopic mucosal resection
Number of subjects: 236

Group type: COMPARATOR
Intervention: Colonoscopy without prophylactic antibiotics
Number of subjects: 236
Study: 27696468

Group type: EXPERIMENTAL
Intervention: Compulsive Exercise Test (CET)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Eating Disorder Examination (EDE)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Eating Disorder Examination-Questionnaire (EDE-Q)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Exercise time per day
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: EDE exercise days
Number of subjects: 78
Study: 26267731

Group type: EXPERIMENTAL
Intervention: Adalimumab (80 mg at week 0, then 40 mg every other week starting at week 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (up to 25 mg/week orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study: 23730899

Group type: EXPERIMENTAL
Intervention: Intervention group (SPACE intervention)
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Control group (comparison schools)
Number of subjects: 1348
Study: 21331473

Group type: EXPERIMENTAL
Intervention: Fast-dissolving azithromycin gelatin capsules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HPMC capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial azithromycin gelatin capsules
Number of subjects: 0
Study: 19705104

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 17
Study: 16983108

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 every 3 weeks
Number of subjects: 571

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 571
Study: 15090933

Group type: EXPERIMENTAL
Intervention: Riluzole (50 mg bid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11561264

Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 66
Study: 9745057

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 40
Study: 8148228

Group type: EXPERIMENTAL
Intervention: Yohimbine (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yohimbine (4 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 0
Study: 2844548

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 500 micrograms/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 1000 micrograms/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 2000 micrograms/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) (all doses)
Number of subjects: 16
Study: 29700575

Group type: EXPERIMENTAL
Intervention: FOLFIRI + aflibercept
Number of subjects: 918

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 918
Study: 28985270

Group type: EXPERIMENTAL
Intervention: Moderate dietary sodium intake (150 mmol/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dietary sodium intake (200-250 mmol/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low dietary sodium intake (60 mmol/day)
Number of subjects: 0
Study: 25058329

Group type: EXPERIMENTAL
Intervention: Overall physical activity (PA) increase
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Reduction in sedentary time
Number of subjects: 150
Study: 23190286

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study: 21386999

Group type: COMPARATOR
Intervention: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET in dyskinetic PD patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET in drug-naïve PD patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Adenosine A(2A) receptor binding ability measured using [(11)C]TMSX PET after antiparkinsonian therapy in drug-naïve PD patients
Number of subjects: 22
Study: 18200673

Group type: EXPERIMENTAL
Intervention: 100 mL/d of 20% alanyl-glutamine dipeptide (AGD) intravenously for 10 days (early treatment group)
Number of subjects: 80
Study: 17186738

Group type: EXPERIMENTAL
Intervention: Medicated bath plus acupoint massage (B-M treatment)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 82
Study: 14620892

Group type: EXPERIMENTAL
Intervention: True echogenic intracardiac focus
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: False echogenic intracardiac focus
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Specular reflection from the moderator band
Number of subjects: 200
Study: 11059521

Group type: EXPERIMENTAL
Intervention: Pharmacist-led asthma training session
Number of subjects: 0

Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 0
Study: 8977061

Group type: EXPERIMENTAL
Intervention: Visual laser ablation of the prostate (VLAP)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 133
Study: 1629993

Group type: EXPERIMENTAL
Intervention: Drug treatments for PTSD
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Behavioral techniques involving direct therapeutic exposure
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 11

Group type: COMPARATOR
Intervention: Behavioral techniques
Number of subjects: 11
Study: 6512252

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol skin preparation
Number of subjects: 519

Group type: COMPARATOR
Intervention: 0.5% chlorhexidine in 70% spirit skin preparation
Number of subjects: 519
Study: 30225805

Group type: EXPERIMENTAL
Intervention: Slow cortical potential neurofeedback (NF) (n=8)
Number of subjects: 15

Group type: COMPARATOR
Intervention: EMG biofeedback control training (C) (n=7)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Successful learners of self-regulation (n=8)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Unmedicated participants
Number of subjects: 15
Study: 29588862

Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing (IUT)
Number of subjects: 218

Group type: COMPARATOR
Intervention: no IUT (clinical assessment plus non-invasive tests)
Number of subjects: 218
Study: 27466039

Group type: EXPERIMENTAL
Intervention: Structured dietary intervention incorporating portion‐controlled foods
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 40
Study: 24524375

Group type: EXPERIMENTAL
Intervention: Lunchtime Enjoyment Activity and Play (LEAP) intervention
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control school
Number of subjects: 275
Study: 23046499

Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle advice, monitoring of blood glucose, and further medical treatment for hyperglycaemia as appropriate.
Number of subjects: 682

Group type: COMPARATOR
Intervention: Routine obstetric care reflecting current clinical practice in Australian hospitals.
Number of subjects: 682
Study: 20329570

Group type: EXPERIMENTAL
Intervention: Oxycodone controlled-release (CR) administered orally twice daily for at least 28 days, dosage individualized and up-titrated over the first week.
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Oxycodone controlled-release (CR)
Number of subjects: 309
Study: 17587425

Group type: EXPERIMENTAL
Intervention: HFA-ciclesonide 400 microg/day
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: HFA-ciclesonide 800 microg/day
Number of subjects: 319

Group type: COMPARATOR
Intervention: CFC-BDP 800 microg/day
Number of subjects: 319
Study: 15584057

Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LW group)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Heavyweight mesh (HW group)
Number of subjects: 321
Study: 16845791

Group type: EXPERIMENTAL
Intervention: Diacerein (100 mg/d)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg/d)
Number of subjects: 223
Study: 10962544

Group type: EXPERIMENTAL
Intervention: Interferon beta‐I b
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Measurement drift identified for one rater
Number of subjects: 33
Study: 8869110

Group type: EXPERIMENTAL
Intervention: 111In‐DTPA‐Octreotide (octreotide scintigraphy)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 19
Study: 1617925

Group type: EXPERIMENTAL
Intervention: roxithromycin 150 mg twice daily
Number of subjects: 194

Group type: COMPARATOR
Intervention: erythromycin 1 g twice daily
Number of subjects: 194
Study: 6150717

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine daily for 5 days
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 1000 mg cimetidine daily for 5 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 30954489

Group type: EXPERIMENTAL
Intervention: Adeno‐associated virus vectored immunoprophylaxis
Number of subjects: 0
Study: 29792754

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 267

Group type: COMPARATOR
Intervention: No bevacizumab
Number of subjects: 267
Study: 26256769

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including nurse care management, use of a patient registry, academic detailing, and electronic tools
Number of subjects: 53

Group type: COMPARATOR
Intervention: Electronic tools alone (control condition)
Number of subjects: 53
Study: 25358916

Group type: EXPERIMENTAL
Intervention: Treatment initiation (pharmacotherapy and/or psychotherapy)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Combination treatment (pharmacotherapy and psychotherapy)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Psychotherapy only
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Clinical severity (CGI-ADHD-S score)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Age, gender, CGI-ADHD-S score
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Parental psychological distress, CSI-4 score, bullying involvement
Number of subjects: 1068
Study: 23154888

Group type: EXPERIMENTAL
Intervention: Levothyroxine oral solution (600 mcg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Levothyroxine tablets (600 mcg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Levothyroxine soft gel capsules (600 mcg)
Number of subjects: 84
Study: 20054522

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention group (INT)
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Conventional treatment group (CON)
Number of subjects: 2033
Study: 18612464

Group type: EXPERIMENTAL
Intervention: Diet-induced weight reduction
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 15814044

Group type: EXPERIMENTAL
Intervention: 2 days of oral ofloxacin (10 mg/kg/day)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 3 days of oral ofloxacin (10 mg/kg/day)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: 4 eligible children infected with Na(R) isolate of S. typhi
Number of subjects: 235
Study: 12091805

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 2 (10 microg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 2 (100 microg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 10335727

Group type: COMPARATOR
Intervention: Cooling (forced air at 15 degrees C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Self-adjust (forced-air warming adjusted to comfort)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (a cotton blanket)
Number of subjects: 9
Study: 8606849

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (CF patients not receiving albuterol therapy)
Number of subjects: 100
Study: 30672801

Group type: EXPERIMENTAL
Intervention: Preventive Program (PP)
Number of subjects: 141

Group type: COMPARATOR
Intervention: No Preventive Program (NPP)
Number of subjects: 141
Study: 28862017

Group type: EXPERIMENTAL
Intervention: Adherence support
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Adherence support and nutritious food supplement
Number of subjects: 643

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 643
Study: 27688102

Group type: EXPERIMENTAL
Intervention: Panitumumab + docetaxel/cisplatin chemotherapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Chemotherapy alone (docetaxel/cisplatin)
Number of subjects: 113
Study: 24754493

Group type: EXPERIMENTAL
Intervention: Coronary plaque volume index (PVI) measured by coronary CT angiography
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) score determined with the Agatston method
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Soft plaque percentage
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Discrepancies between CAC score and PVI rank quartiles
Number of subjects: 224
Study: 23213986

Group type: EXPERIMENTAL
Intervention: Moxibustion 10 min (Group A, n=25)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Moxibustion 20 min (Group B, n=25)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Moxibustion 30 min (Group C, n=26)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 76
Study: 19228091

Group type: EXPERIMENTAL
Intervention: Autologous PRP plus ABM/P-15
Number of subjects: 28

Group type: COMPARATOR
Intervention: Autologous PRP
Number of subjects: 28
Study: 17455405

Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF) plus conventional ultrafiltration (CUF)
Number of subjects: 30
Study: 15678730

Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine with fentanyl 2 microg mL(-1) at 10 mL h(-1) (Group R1, n = 38)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.2% ropivacaine with fentanyl 2 microg mL(-1) at 8 mL h(-1) (Group R2, n = 39)
Number of subjects: 80
Study: 11770217

Group type: EXPERIMENTAL
Intervention: Economic assessment of treatments for lung cancer
Number of subjects: 0
Study: 9640992

Group type: COMPARATOR
Intervention: High-dose alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic treatment with high-dose alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic treatment with lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single high and low doses of alprazolam and lorazepam
Number of subjects: 0
Study: 8136599

Group type: EXPERIMENTAL
Intervention: 1% lidocaine solution
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1% lidocaine plus normal saline solution
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 1% lidocaine plus sodium bicarbonate solution
Number of subjects: 150
Study: 2685688

Group type: EXPERIMENTAL
Intervention: Vindesine (3 mg/m2 i.v.) and Mitoxantrone (10 mg/m2 i.v.) every 3 weeks x 3 and every 4 weeks thereafter (VM)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Vindesine (3 mg/m2 i.v.) and Epirubicin (40 mg/m2 i.v.) every 3 weeks x 3 and every 4 weeks thereafter (VE)
Number of subjects: 230
Study: 806018

Group type: EXPERIMENTAL
Intervention: 3 per cent amino acids
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5 per cent dextrose
Number of subjects: 20
Study: 31307636

Group type: EXPERIMENTAL
Intervention: 320-row area-detector CT (ADCT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 16-row multi-detector CT (MDCT)
Number of subjects: 12
Study: 28406648

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (n = 119)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Dynamic therapy (n = 118)
Number of subjects: 237
Study: 26098588

Group type: EXPERIMENTAL
Intervention: Social resilience training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cultural awareness training
Number of subjects: 48
Study: 23715669

Group type: EXPERIMENTAL
Intervention: Colloid administration (41 patients)
Number of subjects: 413

Group type: COMPARATOR
Intervention: No colloid administration (82 patients)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Positive fluid balance
Number of subjects: 413

Group type: COMPARATOR
Intervention: Negative fluid balance
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Colloid administration
Number of subjects: 413
Study: 20576266

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no hormonal contraception)
Number of subjects: 40
Study: 19223438

Group type: EXPERIMENTAL
Intervention: Switch to venlafaxine
Number of subjects: 334

Group type: COMPARATOR
Intervention: Switch to another SSRI
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (adjunctive)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (adjunctive, N=10)
Number of subjects: 334
Study: 16512804

Group type: EXPERIMENTAL
Intervention: Synbiotics (1.2 x 10^9 CFU Lactobacillus rhamnosus Lcr35 plus prebiotic preparation)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Prebiotics alone (identically appearing prebiotic preparation)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Comparison of Synbiotics vs Prebiotics
Number of subjects: 39
Study: 12972220

Group type: EXPERIMENTAL
Intervention: 12-month intervention
Number of subjects: 386
Study: 10752330

Group type: EXPERIMENTAL
Intervention: FIO2 change from 1.0 to 0.21, then returned to 1.0 (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FIO2 change from 0.8 to 0.4 (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FIO2 change from 1.0 to 0.21 with blood sampling every two minutes (Group 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FIO2 change from 0.8 to 0.4 with blood sampling every two minutes (Group 4)
Number of subjects: 40
Study: 8966047

Group type: EXPERIMENTAL
Intervention: Hypoergic inflammatory response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperergic inflammatory reaction
Number of subjects: 0
Study: 1571645

Group type: EXPERIMENTAL
Intervention: Educational facilitator approach
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Volunteer courier approach
Number of subjects: 264

Group type: COMPARATOR
Intervention: Postal delivery approach
Number of subjects: 264
Study: 3838152

Group type: COMPARATOR
Intervention: Atropine (1 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 29789904

Group type: EXPERIMENTAL
Intervention: Link Endo-Model
Number of subjects: 51

Group type: COMPARATOR
Intervention: EnduRo
Number of subjects: 51
Study: 27345663

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Conventional neck exercises
Number of subjects: 114

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Tai Chi and Conventional neck exercises
Number of subjects: 114
Study: 25516022

Group type: EXPERIMENTAL
Intervention: Specialist Medical and Mental Health Unit
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard geriatric or internal medical wards
Number of subjects: 600
Study: 22762855

Group type: EXPERIMENTAL
Intervention: Generic rosuvastatin 40 mg tablet (Zentiva)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Reference product (Crestor)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both formulations (Generic and Reference)
Number of subjects: 42
Study: 20347483

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis
Number of subjects: 3179
Study: 17921912

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg qd
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1484
Study: 15893095

Group type: EXPERIMENTAL
Intervention: Anabolic steroid prevention program
Number of subjects: 3207

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 3207
Study: 12789994

Group type: EXPERIMENTAL
Intervention: Colgate Simply White Clear Whitening Gel (18% carbamide peroxide), applied for 30 minutes, twice daily, for 3 weeks.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo gel (control group).
Number of subjects: 80
Study: 9585288

Group type: EXPERIMENTAL
Intervention: 1.5 mg of midazolam plus 75 microg of fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3 mL of saline
Number of subjects: 30
Study: 7661944

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 33

Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ultrasound salvage after failed landmark attempts
Number of subjects: 33